瑞巴派特

瑞巴派特
臨床資料
商品名	Mucosta（美国达）、Rebagen（瑞巴根）、Rebagit
AHFS/Drugs.com	国际药品名称
给药途径	口服
ATC碼	A02BX07 (WHO) ;
法律規範狀態
法律規範	处方药;
藥物動力學數據
血漿蛋白結合率	98.4%
药物代谢	肝脏（细胞色素P450）
生物半衰期	约2小时
排泄途徑	肾脏（尿液）
识别信息
	IUPAC命名法 2-[(4-氯苯甲酰)氨基]-3-(2-氧代-1H-喹啉-4-基)丙酸; ;
CAS号	90098-04-7
PubChem CID	5042;
DrugBank	DB11656 ;
ChemSpider	4866 ;
UNII	LR583V32ZR;
KEGG	D01121 ;
ChEMBL	ChEMBL1697745 ;
CompTox Dashboard (EPA)	DTXSID8045937 ;
化学信息
化学式	C19H15ClN2O4
摩尔质量	370.79 g/mol
3D模型（JSmol）	交互式图像;
	SMILES Clc1ccc(cc1)C(=O)NC(C(=O)O)CC2=CC(=O)Nc3ccccc32;
	InChI InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26) ; Key:ALLWOAVDORUJLA-UHFFFAOYSA-N ;

瑞巴派特（英語：Rebamipide）是2-(1H)-喹啉酮的氨基酸衍生物，用于黏膜保护、^[1]治疗消化性溃疡以及胃炎的治疗。^[2]它通过增强黏膜防御、清除自由基^[3]以及暂时激活编码环氧合酶-2（英语：Prostaglandin-endoperoxide synthase 2）（COX-2）的基因来发挥作用。^[4]

研究表明，瑞巴派特可以对抗非甾体抗炎药（NSAIDs）对胃肠道黏膜的损伤作用，^[5]最近的研究还发现其对小肠也有保护作用，但对萘普生引起的胃损伤无效。^[6]

瑞巴派特在多个亚洲国家使用，包括日本（商品名Mucosta）、韩国、中国^[7]和印度（商品名Rebagen）。该药也在俄罗斯获得批准，商品名为Rebagit。^[8]

作用机制

瑞巴派特可增加胃黏膜前列腺素E2的水平，保护胃黏膜，从而抑制胃黏膜损伤，并增加胃黏液分泌和胃黏膜血流量，改善血流动力学障碍，抑制炎症并修复胃黏膜。

参考文献

^ Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (September 1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S. PMID 9753220.
^ Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K (November 1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–72. doi:10.1007/bf02063257. PMID 7587834. S2CID 22807270.
^ Takumida M, Anniko M (January 2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. PMID 18607930. S2CID 16906464.
^ Tarnawski AS, Chai J, Pai R, Chiou SK (February 2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–9. doi:10.1023/b:ddas.0000017439.60943.5c. PMID 15104358. S2CID 31756608.
^ Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, Zhang Y, Chen Y (July 2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. PMID 23456504. S2CID 4887031.
^ Gagliano-Jucá T, Moreno RA, Zaminelli T, Napolitano M, Magalhães AF, Carvalhaes A, Trevisan MS, Wallace JL, De Nucci G (June 2016). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC Gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. PMC 4893238. PMID 27259970.
^ "Rebamipide". Drugs.com.
^ "Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" （俄文）. Russian State Register of Medicines. Retrieved 10 June 2017.

外部链接

Rebamipide Tablets 100mg "Kyorin" - 日本药品信息（日語）
DrugBank: Rebamipide - 药物数据库信息（英文）

[Arakawa1998-1] Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (September 1998). "Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing". Digestive Diseases and Sciences. 43 (9 Suppl): 5S–13S. PMID 9753220.

[Arakawa1995-2] Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K (November 1995). "Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine". Digestive Diseases and Sciences. 40 (11): 2469–72. doi:10.1007/bf02063257. PMID 7587834. S2CID 22807270.

[Takumida2009-3] Takumida M, Anniko M (January 2009). "Radical scavengers for elderly patients with age-related hearing loss". Acta Oto-Laryngologica. 129 (1): 36–44. doi:10.1080/00016480802008215. PMID 18607930. S2CID 16906464.

[Tarnawski2004-4] Tarnawski AS, Chai J, Pai R, Chiou SK (February 2004). "Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?". Digestive Diseases and Sciences. 49 (2): 202–9. doi:10.1023/b:ddas.0000017439.60943.5c. PMID 15104358. S2CID 31756608.

[Zhang2013-5] Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, Zhang Y, Chen Y (July 2013). "Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis". Digestive Diseases and Sciences. 58 (7): 1991–2000. doi:10.1007/s10620-013-2606-0. PMID 23456504. S2CID 4887031.

[Gagliano2016-6] Gagliano-Jucá T, Moreno RA, Zaminelli T, Napolitano M, Magalhães AF, Carvalhaes A, Trevisan MS, Wallace JL, De Nucci G (June 2016). "Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial". BMC Gastroenterology. 16 (1): 58. doi:10.1186/s12876-016-0472-x. PMC 4893238. PMID 27259970.

[Drugs.com-7] "Rebamipide". Drugs.com.

[Russia-8] "Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets" （俄文）. Russian State Register of Medicines. Retrieved 10 June 2017.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]